New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus
D Durantel, F Zoulim - Journal of hepatology, 2016 - Elsevier
Current therapies of chronic hepatitis B (CHB) remain limited to pegylated-interferon-alpha
(PegIFN-α) or any of the five approved nucleos (t) ide analogues (NUC) treatments. While
viral suppression can be achieved in the majority of patients with the high-barrier-to-
resistance new-generation of NUC, ie entecavir and tenofovir, HBsAg loss is achieved by
PegIFN-α and/or NUC in only 10% of patients, after a 5-year follow-up. Attempts to improve
the response by administering two different NUC or a combination of NUC and PegIFN-α …
(PegIFN-α) or any of the five approved nucleos (t) ide analogues (NUC) treatments. While
viral suppression can be achieved in the majority of patients with the high-barrier-to-
resistance new-generation of NUC, ie entecavir and tenofovir, HBsAg loss is achieved by
PegIFN-α and/or NUC in only 10% of patients, after a 5-year follow-up. Attempts to improve
the response by administering two different NUC or a combination of NUC and PegIFN-α …